Drug Shortage Report for BIVALIRUDIN FOR INJECTION
| Report ID | 201032 |
| Drug Identification Number | 02435268 |
| Brand name | BIVALIRUDIN FOR INJECTION |
| Common or Proper name | BIVALIRUDIN FOR INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | BIVALIRUDIN |
| Strength(s) | 250MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10mL |
| ATC code | B01AE |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2023-07-21 |
| Estimated end date | 2023-11-30 |
| Actual end date | 2023-11-17 |
| Shortage status | Resolved |
| Updated date | 2023-11-18 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Bivalirudin for Injection 250 mg/vial SD Vial 10 mL effective July 21, 2023, until November 30, 2023. Sandoz is an alternate supplier of Bivalirudin and have been informed of our impending supply interruption. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v9 | 2023-11-18 | English | Compare |
| v8 | 2023-11-17 | French | Compare |
| v7 | 2023-11-17 | English | Compare |
| v6 | 2023-11-01 | French | Compare |
| v5 | 2023-11-01 | English | Compare |
| v4 | 2023-08-25 | French | Compare |
| v3 | 2023-08-25 | English | Compare |
| v2 | 2023-08-03 | French | Compare |
| v1 | 2023-08-03 | English | Compare |
Showing 1 to 9 of 9